ELAN · NYSE · STOCK
Elanco (ELAN) Stock Analysis
$22.91
52W $19.40 – $27.98
58/100
$11.45B
-55.9
1.71
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ELAN Bullish or Bearish?
Bullish.
Innellis AI committee rates Elanco (ELAN) Buy with a composite score of 58/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.66 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.34 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Supporting evidence favours the bullish case. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.17 across 6 articles, 14d) — News
Bear Case
- ROE of only -3.0% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
58/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 42%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -3.0% -- cheap may mean cheap for a reason
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 6 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.3 to 58.3.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
60.2
Neutral
MACD Histogram
0.095
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$21.32
Resistance
$23.66
Bollinger %B
0.79
Inside Bands
Price vs Moving Averages
EMA 9
$22.53
Above
EMA 21
$22.72
Above
EMA 50
$23.25
Below
EMA 200
$22.90
Above
Fundamental Analysis
Valuation
99
Growth
75
Profitability
20
Financial Health
98
Cash Flow
70
Valuation
P/E Ratio
-55.9×
P/B Ratio
1.74×
PEG Ratio
0.35
Dividend Yield
0.00%
52W High
$27.98
52W Low
$19.40
Quality & Growth
ROE
-354.4%
ROA
-173.7%
Gross Margin
5259.0%
Operating Margin
920.3%
Revenue Growth YoY
—
Debt / Equity
0.59
AI Fundamental Assessment
P/E ratio of -55.9 (inexpensive relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -3.5%; Return on assets of -1.7%; Net margin of -4.0%; Gross margin of 52.6%; Current ratio of 2.05 (healthy short-term liquidity); Debt-to-equity of 0.59; Free cash flow per share is positive (0.76); Most recent quarter beat estimates by 23.8%; 5 consecutive earnings beats; EPS growth decelerating (+207.7% -> -15.0% QoQ); Average YoY EPS growth of 30.8%; Analyst estimates rising over recent quarters
Get the Full ELAN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →